Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCENDI trial
Stephen B. Hanauer*, William J. Sandborn, Christian Dallaire, André Archambault, Bruce Yacyshyn, Chyon Yeh, Nancy Smith-Hall
Dive into the research topics of 'Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared with 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCENDI trial'. Together they form a unique fingerprint.